This site is intended for Healthcare professionals only.

Dr Reddy’s Laboratories Announces Launch of Bivalirudin for Injection in US Market


Dr Reddy’s Laboratories Announces Launch of Bivalirudin for Injection in US Market

Hyderabad & Princeton: Dr. Reddy’s Laboratories Ltd. announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax® (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health.

Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.

Angiomax® is a registered trademark of The Medicines Company.



Source: PRESS RELEASE
0 comment(s) on Dr Reddy’s Laboratories Announces Launch of Bivalirudin for Injection in US Market

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted